NASDAQ:ENLV

Enlivex Therapeutics (ENLV) Stock Price, News & Analysis

Enlivex Therapeutics logo
$1.05 -0.12 (-10.26%)
Closing price 04:00 PM Eastern
Extended Trading
$1.07 +0.02 (+1.52%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Enlivex Therapeutics Stock (NASDAQ:ENLV)

Advanced

Key Stats

Today's Range
$1.05
▼
$1.22
50-Day Range
$1.12
▼
$15.35
52-Week Range
$1.00
▼
$434.40
Volume
39,970 shs
Average Volume
25,089 shs
Market Capitalization
$1.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4,800.00
Consensus Rating
Hold

Company Overview

Enlivex Therapeutics is an Israel-based clinical-stage biotechnology company developing cell therapies intended to regulate immune responses. Its lead candidate, Allocetra-OTS, is an investigational, off-the-shelf therapy made from apoptotic cells and designed to help restore immune balance by influencing the activity of immune cells called macrophages.

The company has investigated Allocetra-OTS for conditions involving severe immune dysregulation, including sepsis, and has also pursued research in other therapeutic areas. The treatment remains investigational and is not an approved medicine.

Enlivex conducts its research and development in Israel and advances its programs through clinical studies and collaborations. Its work focuses on developing cell-based approaches for diseases that lack effective treatment options.

AI Generated. May Contain Errors.

Enlivex Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

ENLV MarketRank™: 
2.524311738115 of 5 stars

Enlivex Therapeutics scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enlivex Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Enlivex Therapeutics has a consensus price target of $4,800.00, representing about 432,332.4% upside from its current price of $1.11.

  • Amount of Analyst Coverage

    Enlivex Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Enlivex Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Enlivex Therapeutics are expected to grow in the coming year, from ($18.40) to ($3.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enlivex Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enlivex Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enlivex Therapeutics has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Enlivex Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.68% of the float of Enlivex Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Enlivex Therapeutics has a short interest ratio ("days to cover") of 0.47, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enlivex Therapeutics has recently decreased by 85.80%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enlivex Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Enlivex Therapeutics does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Enlivex Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for ENLV on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    1.02% of the stock of Enlivex Therapeutics is held by institutions.

  • Read more about Enlivex Therapeutics' insider trading history.
Receive ENLV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ENLV Stock News Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Headlines

ENLV Stock Analysis - Frequently Asked Questions

Enlivex Therapeutics' stock was trading at $168.7680 at the beginning of 2026. Since then, ENLV stock has decreased by 99.3% and is now trading at $1.11.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) announced its quarterly earnings data on Friday, November, 14th. The company reported ($22.18) EPS for the quarter, topping analysts' consensus estimates of ($28.80) by $6.62.

Enlivex Therapeutics shares reverse split on the morning of Thursday, July 9th 2026.The 1-15 reverse split was announced on Tuesday, July 7th 2026. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Enlivex Therapeutics (ENLV) raised $38 million in an IPO on Wednesday, July 30th 2014. The company issued 3,200,000 shares at $11.00-$13.00 per share.

Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), NVIDIA (NVDA), C3.ai (AI), Alibaba Group (BABA), Carnival (CCL) and Southwest Airlines (LUV).

Company Calendar

Today
11/20/2026
Next Earnings (Estimated)
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ENLV
CIK
1596812
Employees
34
Year Founded
2012

Price Target and Rating

High Price Target
$4,800.00
Low Price Target
$4,800.00
Potential Upside/Downside
+457,042.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
119.39
Quick Ratio
119.39

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1,955.31 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
1,532,000
Free Float
1,344,000
Market Cap
$1.61 million
Optionable
Optionable
Beta
1.63

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:ENLV) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners